202 related articles for article (PubMed ID: 37357809)
1. Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma.
Takamoto T; Maruki Y; Kondo S
Expert Opin Pharmacother; 2023; 24(14):1567-1575. PubMed ID: 37357809
[TBL] [Abstract][Full Text] [Related]
2. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
[TBL] [Abstract][Full Text] [Related]
3. Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability.
Lau WY; Lai EC
Ann Surg Oncol; 2007 Dec; 14(12):3301-9. PubMed ID: 17891443
[TBL] [Abstract][Full Text] [Related]
4. Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview.
Sun HC; Zhu XD
Front Oncol; 2021; 11():772195. PubMed ID: 34869008
[TBL] [Abstract][Full Text] [Related]
5. Radioembolization for Hepatocellular Carcinoma in Downstaging and Bridging for Liver Transplantation.
Kutlu R; Karatoprak S
J Gastrointest Cancer; 2020 Dec; 51(4):1157-1164. PubMed ID: 32880041
[TBL] [Abstract][Full Text] [Related]
6. Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma.
Tang ZY; Zhou XD; Ma ZC; Wu ZQ; Fan J; Qin LX; Yu Y
Hepatobiliary Pancreat Dis Int; 2004 Nov; 3(4):495-8. PubMed ID: 15567731
[TBL] [Abstract][Full Text] [Related]
7. Radioembolization using yttrium-90 microspheres as bridging and downstaging treatment for unresectable hepatocellular carcinoma before liver transplantation: initial single-center experience.
Abdelfattah MR; Al-Sebayel M; Broering D; Alsuhaibani H
Transplant Proc; 2015 Mar; 47(2):408-11. PubMed ID: 25769582
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model.
Lin H; Luo B; Peng F; Fang C; Gan Y; Yang X; Li B; Li Y; Su S
Invest New Drugs; 2022 Oct; 40(5):1146-1152. PubMed ID: 35723760
[TBL] [Abstract][Full Text] [Related]
9. Liver Transplantation after Successful Downstaging of a Locally Advanced Hepatocellular Carcinoma with Systemic Therapy.
Schmiderer A; Zoller H; Niederreiter M; Effenberger M; Oberhuber G; Krendl FJ; Oberhuber R; Schneeberger S; Tilg H; Djanani A
Dig Dis; 2023; 41(4):641-644. PubMed ID: 36646054
[TBL] [Abstract][Full Text] [Related]
10. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
[TBL] [Abstract][Full Text] [Related]
11. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
[TBL] [Abstract][Full Text] [Related]
12. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy.
Clavien PA; Selzner N; Morse M; Selzner M; Paulson E
Surgery; 2002 Apr; 131(4):433-42. PubMed ID: 11935134
[TBL] [Abstract][Full Text] [Related]
13. Downstaging Hepatocellular Carcinoma before Transplantation: Role of Immunotherapy Versus Locoregional Approaches.
Lindemann J; Yu J; Doyle MBM
Surg Oncol Clin N Am; 2024 Jan; 33(1):143-158. PubMed ID: 37945140
[TBL] [Abstract][Full Text] [Related]
14. Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody.
Xu B; Zhu XD; Shen YH; Zhu JJ; Liu J; Li ML; Tang PW; Zhou J; Fan J; Sun HC; Huang C
Front Immunol; 2022; 13():1016736. PubMed ID: 36505445
[TBL] [Abstract][Full Text] [Related]
15. The place of downstaging for hepatocellular carcinoma.
Toso C; Mentha G; Kneteman NM; Majno P
J Hepatol; 2010 Jun; 52(6):930-6. PubMed ID: 20385428
[TBL] [Abstract][Full Text] [Related]
16. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.
Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Saito Y; Imura S; Bando Y; Shimada M; Takayama T
Medicine (Baltimore); 2020 Oct; 99(42):e22782. PubMed ID: 33080748
[TBL] [Abstract][Full Text] [Related]
17. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation.
Sharr WW; Chan SC; Lo CM
Transplantation; 2014 Apr; 97 Suppl 8():S10-7. PubMed ID: 24849822
[TBL] [Abstract][Full Text] [Related]
18. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.
Pompili M; Francica G; Ponziani FR; Iezzi R; Avolio AW
World J Gastroenterol; 2013 Nov; 19(43):7515-30. PubMed ID: 24282343
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant systemic therapy for hepatocellular carcinoma.
Chick RC; Ruff SM; Pawlik TM
Front Immunol; 2024; 15():1355812. PubMed ID: 38495884
[TBL] [Abstract][Full Text] [Related]
20. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
Chan LL; Chan SL
Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
